Celltrion wins UNDP tender to supply anticancer treatments to Turkmenistan
Celltrion Healthcare, South Korean biosimilar giant Celltrion’s sales unit, announced Wednesday that the company has won the United Nations Development Program’s tender to supply anticancer drugs to Turkmenistan.
The UNDP is a UN agency dedicated to eradicating poverty and reducing inequalities through the sustainable development of nations in more than 170 countries and territories.
Celltrion Healthcare said the company joined the tender that opened in May this year, and that the result was announced last month.
According to Celltrion Healthcare, the company will supply its blood cancer biosimilar Truxima, and its metastatic colorectal and breast cancer treatment Vegzelma to Turkmenistan.
The company added that the supply of anticancer biosimilars is expected to begin by the end of this year.
The value of the tender, as well as the quantity of its anticancer treatments supply, have not been disclosed by the company.
“It is meaningful for us to supply our treatments to help patients in the country,” an official from Celltrion Healthcare said. “We believe that Truxima and Vegzelma will become the most effective, and economically viable treatment options, not only in developed countries but also in developing countries."
Celltrion Healthcare said that the company will participate more in international organizations’ tenders in the future.
Both Truxima and Vegzelma are widely prescribed anticancer treatments developed by Celltrion.
According to the world’s largest contract research organization IQVIA’s data, Truxima, the first biosimilar of Roche’s blockbuster cancer drug Rituxan, has secured 22 percent market share in the European market as of the second quarter this year. In the US, its market share stood at 30 percent in the third quarter, according to separate data from Symphony Health.
Vegzelma, an anti-cancer monoclonal antibody treatment biosimilar to Avastin, is increasing its presence in European countries after its launch in October 2022, Celltrion Healthcare said. The drug's market shares in Finland and Germany stood at 45 percent and 21 percent, respectively.
(责任编辑:예술)
- ·S. Korea, AIIB discuss stronger partnership, new investment chances
- ·[KH explains] Hyundai to sell vehicles on Amazon in US sales push
- ·‘Smugglers’ wins best picture at 44th Blue Dragon Film Awards
- ·Two dead in Gyeongju construction site collapse
- ·김용민 “尹, 총선 승리하면 계엄 선포할 것…저지선 확보해야”
- ·[Herald Interview] Korea ramps up high
- ·Korea to start hiring E
- ·NYT picks Yoon as one of most stylish people of 2023
- ·Enhypen announces Nov. 17 comeback with 'Orange Blood'
- ·S. Korea joins ICRC's major donor group for 1st time
- ·"당 망치는 응석받이"…안철수, 이준석 제명 서명운동 시작
- ·[News Focus] Why Kim Jong
- ·Seoul to implement alert system to manage overcrowded areas
- ·[Coffee Klatch] Take a sip of Turkish coffee in Seoul
- ·Seoul shares open lower ahead of earnings season
- ·Actors, musicians unite for Hakchon Theater's closing act
- ·[Coffee Klatch] Take a sip of Turkish coffee in Seoul
- ·Seoul stocks end nearly flat on cautious note
- ·HMM sale to face hurdles amid slowdown in shipping industry
- ·北, 러 주최 국제포럼서 '국제수송' 논의…무기거래 우회로 찾나
- ·SK Ecoplant recycles over 6,000 tons of batteries
- ·Yoon nominates former boss to head broadcasting watchdog
- ·[Obituary] Park Seo
- ·S. Korea entering 'recovery phase' amid geopolitical uncertainties: Choo
- ·"당 망치는 응석받이"…안철수, 이준석 제명 서명운동 시작
- ·Mirae Asset Securities names new CEOs
- ·Gyeongbokgung entrance platform, new signboard unveiled